GILD - Gilead Sciences, Inc
An antiviral drug specialist best known for HIV and hepatitis C treatments, now expanding into oncology and inflammation through acquisitions and internal R&D.
Finlify Score
48.4 / 100
Data Quality
FULL
Penalty
0.0
Sector
Health Care
Close Price
$143.72
-0.75%
52W Range
$108.46 - $157.29
Market Cap
$181.5B
-0.8%Compared to previous day
2026 Q1 Revenue
$7.0B
-12.2%Changes from last reporting quarter
2026 Q1 EPS
$1.61
Diluted shares
Analyst Rating
37 analysts in latest ratings feed
RSI
44.3
40-70 moderate
2Y Range Position
82%
-8.6% from high / +75.6% from low
Beta
0.40
Relative to market benchmark
MACD
-0.93
MACD line 2.60 / signal line 3.53
Fundamental Trend
Growth 35.7Financial Health
Quality 87.6Data Quality
FULLValuation Reference
Price Chart
Close price, two-year source window
Finlify Score
HOLD48.4 / 100
Score History
Finlify Score and component trend
Financial Statements
Calendar year view. Figures are estimates only. For official figures, refer to the company website.
| 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | |
|---|---|---|---|---|
| Revenue | $7.0B-12.2% | $7.9B+2.0% | $7.8B+9.7% | $7.1B+6.2% |
| Gross Profit | - | - | - | - |
| Operating Income | $2.6B+30.3% | $2.0B-40.4% | $3.3B+34.5% | $2.5B+10.6% |
| Net Income | $2.0B-7.4% | $2.2B-28.5% | $3.1B+55.7% | $2.0B+49.0% |
Columns use the calendar quarter of each reported period end date. QoQ is shown for adjacent company reporting quarters only.
AI Signal
Generated Aug 1, 2026
Finlify's signal for Gilead Sciences, Inc (GILD) on 2026-07-30 is AVOID, with an overall Finlify Score of 41.5/100. This score appears to be influenced by lower component scores in Relative Strength, Accumulation / Volume, and Fundamental Trend.
Technical
The asset's technical posture appears weak, with a Relative Strength score of 25.0/100 and an Accumulation / Volume score of 23.1/100. While the 20-day return shows a positive 4.2%, the 60-day return indicates a slight decline of -1.1%, and the stock remains -15.7% from its 52-week high.
Fundamentals
Despite a strong Financial Quality score of 87.6/100, the Fundamental Trend component is relatively low at 35.7/100, based on the latest financial period ending 2026-03-31. GILD trades at a P/E of 19.0x and offers a Dividend Yield of 2.50%, with a low Beta of 0.3 suggesting lower volatility relative to the broader market.
Macro Context
The current macro environment, with a 10Y Treasury Yield at 4.7% and Core CPI YoY at 2.8%, may present a challenging backdrop for equity valuations. However, GILD's low Beta of 0.3 could suggest some potential resilience in a higher interest rate or inflationary environment.
Key Risks
- Weak technical momentum, as indicated by low Relative Strength (25.0/100) and Accumulation / Volume (23.1/100) scores.
- A lower Fundamental Trend score (35.7/100) suggests potential concerns regarding underlying business performance despite high financial quality.
- Upcoming earnings announcement on 2026-08-04 could introduce significant volatility.